Nordea Investment Management AB boosted its position in Cambrex Co. (NYSE:CBM) by 27.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 40,310 shares of the biotechnology company’s stock after purchasing an additional 8,740 shares during the period. Nordea Investment Management AB owned about 0.12% of Cambrex worth $2,217,000 as of its most recent SEC filing.
Several other large investors also recently bought and sold shares of CBM. Nisa Investment Advisors LLC lifted its position in shares of Cambrex by 9.3% during the second quarter. Nisa Investment Advisors LLC now owns 1,760 shares of the biotechnology company’s stock worth $105,000 after acquiring an additional 150 shares in the last quarter. Creative Planning raised its position in shares of Cambrex by 162.6% in the second quarter. Creative Planning now owns 1,765 shares of the biotechnology company’s stock worth $105,000 after buying an additional 1,093 shares in the last quarter. YorkBridge Wealth Partners LLC raised its position in shares of Cambrex by 5.2% in the second quarter. YorkBridge Wealth Partners LLC now owns 1,971 shares of the biotechnology company’s stock worth $118,000 after buying an additional 97 shares in the last quarter. Riverhead Capital Management LLC raised its position in shares of Cambrex by 90.3% in the second quarter. Riverhead Capital Management LLC now owns 2,664 shares of the biotechnology company’s stock worth $159,000 after buying an additional 1,264 shares in the last quarter. Finally, Advisor Group Inc. raised its position in shares of Cambrex by 29.8% in the second quarter. Advisor Group Inc. now owns 2,681 shares of the biotechnology company’s stock worth $160,000 after buying an additional 615 shares in the last quarter.
A number of equities research analysts recently issued reports on CBM shares. BidaskClub downgraded Cambrex from a “hold” rating to a “sell” rating in a research report on Thursday, August 24th. ValuEngine upgraded Cambrex from a “hold” rating to a “buy” rating in a research report on Tuesday, August 22nd. Finally, Craig Hallum reiterated a “buy” rating and issued a $60.00 price objective (down previously from $70.00) on shares of Cambrex in a research report on Tuesday, October 31st. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $62.33.
Cambrex Co. (NYSE CBM) opened at $49.00 on Thursday. The company has a market capitalization of $1,602.82, a price-to-earnings ratio of 15.43, a P/E/G ratio of 1.10 and a beta of 2.26. Cambrex Co. has a 12 month low of $42.55 and a 12 month high of $62.95.
Cambrex (NYSE:CBM) last released its earnings results on Tuesday, November 7th. The biotechnology company reported $0.55 EPS for the quarter, beating the Zacks’ consensus estimate of $0.47 by $0.08. The business had revenue of $112.60 million for the quarter, compared to analysts’ expectations of $108.44 million. Cambrex had a return on equity of 23.42% and a net margin of 18.79%. The firm’s revenue was up 13.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.47 earnings per share. equities analysts anticipate that Cambrex Co. will post 2.97 earnings per share for the current fiscal year.
In related news, CEO Steven M. Klosk sold 4,000 shares of the stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $54.96, for a total value of $219,840.00. Following the transaction, the chief executive officer now owns 87,328 shares of the company’s stock, valued at $4,799,546.88. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 2.48% of the stock is owned by corporate insiders.
TRADEMARK VIOLATION NOTICE: This piece was first posted by Stock Observer and is owned by of Stock Observer. If you are reading this piece on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The legal version of this piece can be viewed at https://www.thestockobserver.com/2017/12/07/cambrex-co-cbm-shares-bought-by-nordea-investment-management-ab.html.
Cambrex Company Profile
Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.
Receive News & Ratings for Cambrex Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Co. and related companies with MarketBeat.com's FREE daily email newsletter.